Showing 1,961 - 1,980 results of 3,158 for search 'Patient Number 9', query time: 0.10s Refine Results
  1. 1961
  2. 1962

    A Study to Assess Resilience and Empathy among the BSc Nursing Students by S. Anand, K. R. Anoopa, J. P Haripriya

    Published 2024-01-01
    “…The Percentage of the student in the first year is 27.3%, while the number who belongs to the 3rd year is 25.8% and equal number of students belongs to 4th year. …”
    Get full text
    Article
  3. 1963

    Efficiency of Automated Viral RNA Purification for Pediatric Studies of Dengue and Zika in Hyperendemic Areas by Sandra L. Delgado, Piedad M. Perilla, Doris M. Salgado, María Clemencia Rojas, Carlos F. Narváez

    Published 2023-01-01
    “…The concentration of RNA (5.2 vs. 7.5 ng/μL, P=0.03) and the number of integral bands (9 vs. 11) were higher with the high-throughput protocol. …”
    Get full text
    Article
  4. 1964

    Immunoprotection of mice against Schistosomiasis mansoni using solubilized membrane antigens. by Guidenn Sulbarán, Oscar Noya, Beatríz Brito, Diana E Ballén, Italo M Cesari

    Published 2013-01-01
    “…As compared to control, a significantly lower number of perfuse parasites was obtained in the immunized/challenged mouse group (P<0.05, t test); and consequently, a lower number of eggs and granulomas (with reduced sizes), overall decreasing pathology. …”
    Get full text
    Article
  5. 1965
  6. 1966
  7. 1967
  8. 1968

    Polypharmacy or potentially inappropriate medications among older adults with COVID-19 in a secondary hospital in China and their association with mortality by Mian Mao, Shan Du, Yue Xu, Qiu Li, Ruoxi Luo, Qiaoqiao Zhou, Xiaoli Hu

    Published 2025-01-01
    “…Abstract Elderly patients with multiple concomitant chronic diseases are the particularly vulnerable during the Coronavirus disease 2019 (COVID-19) epidemic, which accounts for a large number of COVID-19-related deaths. …”
    Get full text
    Article
  9. 1969

    Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion by Sylvia Nghiem-Buffet, Agnès Glacet-Bernard, Manar Addou-Regnard, Eric H. Souied, Salomon Y. Cohen, Audrey Giocanti-Auregan

    Published 2018-01-01
    “…After switching to aflibercept, patients received a mean number of 12.4 injections (range, 6–20) during a mean follow-up of 25.5 months (range, 16–38). …”
    Get full text
    Article
  10. 1970
  11. 1971
  12. 1972
  13. 1973

    Congenital muscular dystrophies and myopathies: the leading cause of genetic muscular disorders in eleven Chinese families by Bin Mao, Xiaoling Cai, Na Lin, Yulin Jiang, Na Hao, Yifang Dai, Danhua Guo, Deqin He, Huili Xue, Lingji Chen, Qianqian He, Min Zhang, Meihuan Chen, Hailong Huang, Liangpu Xu

    Published 2025-01-01
    “…Conclusions CMDs and CMYOs were probably responsible for most of the cases (9/11) of genetic muscular defects in this study. …”
    Get full text
    Article
  14. 1974
  15. 1975

    Hepatorenal syndrome in decompensated portal hypertension by M.I. Tutchenko, M.S. Besedinskyi, S.A. Aslanian, I.V. Kluzko, D.V. Rudyk, S.L. Chub

    Published 2024-12-01
    “…Renal dysfunction and increased creatinine were detected in 192 (43.9%) out of 437 patients with decompensated portal hypertension, who were subsequently divided into two groups based on the degree of decompensation. …”
    Get full text
    Article
  16. 1976
  17. 1977
  18. 1978

    Potentially inappropriate prescribing in hospitalised children: a retrospective, cross-sectional study at a tertiary children’s hospital in China by Linan Zeng, Lingli Zhang, Dan Yu, Huiqing Wang, Liang Huang, Siyu Li, Guo Cheng, Zhi-Jun Jia

    Published 2023-05-01
    “…Logistic regression results showed that PIP was more likely to occur in male patients (OR 1.128, 95% CI 1.059 to 1.202) and younger patients (&lt;2 years old; OR 1.974; 95% CI 1.739 to 2.241), and in those with more comorbidities (≥11 types; OR 4.181; 95% CI 3.671 to 4.761), concomitant drugs (≥11 types; OR 22.250; 95% CI 14.468 to 34.223) or longer hospital stay (≥30 days; OR 8.130; 95% CI 6.727 to 9.827).Conclusions Medications for long-term hospitalised young children with multiple comorbidities should be minimised and optimised, to avoid PIP, reduce adverse drug reactions and ensure children’s medication safety. …”
    Get full text
    Article
  19. 1979
  20. 1980

    THERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES by Ugo Testa, Giuseppe Leone, Maria Domenica Cappellini

    Published 2024-08-01
    “… In the last ten years, a consistent number of clinical studies have evaluated different gene approaches for the treatment of patients with sickle cell disease (SCD) and transfusion-dependent b-thalassemia (TDT). …”
    Get full text
    Article